Cystic fibrosis (CF) is a genetic condition characterised by the build-up of thick, sticky mucus that can damage many of the body’s organs. It is a life-long disease that results in a shortened life expectancy, often due to the progression of advanced lung disease. Treatment has previously targeted the downstream symptoms such as diminished mucus clearance and recurrent infection. More recently, significant advances have been made in treating the cause of the disease by targeting the faulty gene responsible. Hope for the development of potential therapies lies with ongoing research into new pharmacological agents and gene therapy. This review gives an overview of CF, and summarises the current evidence regarding the disease management and upcoming strategies aimed at treating or potentially curing this condition.

Key words: Cystic fibrosis; CFTR; treatment; infection; gene therapy.
Introduction

Cystic fibrosis (CF) is a life-long condition characterised primarily by a build-up of mucus in the lungs and digestive tracts [1]. The body’s failure to remove this often leads to breathing difficulties and frequent lung infections [2]. Unfortunately, these manifestations become chronic as patients progress through life, with pulmonary disease and respiratory failure remaining the major cause of morbidity and mortality [3]. Currently, there is no cure for CF, however with good management, patients often live well into adulthood with the average predicted survival standing at 48 years for males and 43 years for females [4]. Yet, the demanding routine patients must go through to control their symptoms often has deleterious effects on their physical and mental wellbeing. Ongoing research is trying to explore how we can minimise these problems, focusing on how best to manage, treat and possibly cure CF.

The aim of this review is to critically discuss the current evidence on the therapeutic strategies for managing CF. Firstly, we provide an overview of CF in relation to its clinical presentation and pathophysiology and then look at the current options available for treatment. We will then explore future therapies, where emphasis may be given towards how we can target the underlying mechanisms of this genetic condition by focusing on pharmacological interventions that are currently undergoing investigation.

Prevalence of CF

Various countries have introduced registers which track the number of patients diagnosed with CF [5-7]. These help to measure, appraise and compare aspects of cystic fibrosis, its diagnosis, and its treatment regimen, thereby encouraging new procedures to deal with this disease. Most countries within Africa, South America and parts of Asia have a limited or non-existent system due to health authorities prioritising other important public health issues; poverty, malnutrition, civil war, and outbreaks of infectious diseases are among the reasons for this [8]. For these reasons, the most accurate data concerning the prevalence of CF is usually found in countries within Europe and North America.

Each year, the European Cystic Fibrosis Society Patient Registry collects data on CF patients and causative mutations from Europe and neighbouring countries [5]. In the 2017 report [9], the number of CF patients registered totalled 48,204, though the amount is certain to be higher due to coverage varying from different countries [10]. In Romania for example, there is an estimated 35% coverage in comparison to the UK which has a coverage of more than 95% [9]. Overall, the F508del mutation is the most frequent, with approximately 80% of patients detected as being F508del heterozygous and around 40% as being F508del homozygous. This is in comparison to the G542X allele mutation, the second most common, for which 2.69% of patients tested positive and N1303K with 2.19%, although it should be noted that the geographical differences of these variants can differ.

The frequency of CF in North America is similar to Europe, affecting 1 in 2,500-3,500 people [11,12]. However, there are differences in its distribution across the North American continent. This is primarily linked to ethnic group; the Caucasian population has a higher prevalence than other ethnicities, including Hispanics, Native Americans and those of African or Caribbean ancestry [8]. Consequently, as with Europe, North America’s most prevalent mutation is the F508del mutation. The 2018 US Cystic Fibrosis Foundation Patients Registry report found that, in those genotyped, 84.7% of those in the registry had at least one F508del mutation, with 44.2% of those being homozygous for F508del [13]. There is a substantial drop in the next prevalent mutations which are G542X, G551D and R117H. These are found to be at a prevalence of 4.6%, 4.4% and 3.0% of the CF population, respectively. Due to its high frequency among Caucasian populations, it is the most common, potentially lethal inherited condition in this demographic [14].

Pathophysiology

Cystic fibrosis is an autosomal recessive disorder caused by a mutation on chromosome 7 at position q31.2 [15]. This location contains the cystic fibrosis transmembrane conductance regulator (CFTR) gene which is 189 kb in length with 27 exons and 26 introns. The protein itself is made of 1,480 amino acids and consists of five domains. There are two transmembrane domains that are each connected to a nucleotide binding domain (NBD) in the cytoplasm. The first NBD is connected to the second transmembrane domain by a regulatory ‘R’ domain. For the channel to open, serine residues on the ‘R’ domain must be phosphorylated by a cAMP-dependent protein kinase and ATP must bind to both NBDs and be subsequently hydrolysed [16]. In its open state, the channel is responsible for the transport of anions, specifically bicarbonate and chloride ions, across the cell membrane [17].Physiologically, chloride and bicarbonate ions are secreted onto the epithelial surface by the CFTR channel resulting in the secretion of fluid through osmosis. Any impairment in CFTR function may therefore lead to a decrease in CFTR-mediated chloride and bicarbonate secretion. Water resorption follows, creating a thick, viscous mucus which accumulates on the epithelial surfaces of bodily organs such as the lungs, liver, intestines and pancreas [18]. The CFTR channel is also involved in the regulation of the epithelial sodium channel (ENaC), otherwise known as the amiloride-sensitive sodium channel, found in the airways of the lungs [19].

While CF is a multi-organ disease, the dominant cause of morbidity and mortality is its effects on the lungs [20]. In the airways of the lungs, CFTR is highly expressed, where the build-up of mucus often causes breathing difficulties and increases the risk of infections. The airways are predominantly lined by pseudostratified columnar epithelium [21]. This epithelium is composed of numerous cell types including basal cells, club cells, ciliated cells, goblet cells, and pulmonary neuroendocrine cells (PNECs) amongst others. The pulmonary ionocytes are of particular importance to CF. These cells are derived from basal cells and are responsible for most of the CFTR expression in the airway epithelium. It is therefore thought that pulmonary ionocytes are heavily involved in fluid regulation and may play a critical role in the pathogenesis of CF [22].

Mucus build-up is primarily driven by dehydration of the airway surface liquid (ASL) that coats the epithelial cells of the airways. Hydration of the ASL is primarily regulated by CFTR-mediated anion secretion and ENaC-mediated sodium absorption. In CF, an increase in ENaC-mediated sodium absorption into the airway epithelial cells has been found alongside CFTR dysfunction, contributing to the dehydration of ASL [23]. This is thought to be due to the abolition of ENaC regulation by the CFTR channel, when CFTR is mutated and dysfunctional, as seen in CF [24]. The ASL is composed of a periciliary layer (PCL) that is covered with a mucus layer (ML) [25]. The ML is composed of mucins that form a gel-like structure and are involved in trapping inhaled particles, while the PCL covers the cilia, preventing penetration by those inhaled particles. This allows the cilia to beat to remove inhaled particles through mucociliary clearance. Dehydration of the ASL leads to a decrease in PCL volume, resulting in the dehydrated ML compressing the cilia. This ultimately results in a decrease in the ability of the cilia to beat, thickened mucus, mucus stasis, and...
Diagnosis of CF

There are several tests that can be utilised for diagnosing CF. Babies are screened for CF using the heel prick test and, as a result, most children are diagnosed shortly after birth. The test itself involves taking blood from the baby’s heel at around 5 days of age, which is then sampled for several conditions including CF. The first stage of testing involves the measurement of Immunoreactive Trypsinogen (IRT) levels, which are raised in CF patients due to the stage of testing involves the measurement of Immunoreactive Trypsinogen (IRT) levels, which are raised in CF patients due to the destruction of the vas deferens and epididymis are responsible for 95% of male CF patients being infertile [29]. In females, the reproductive systems are also not spared.

Clinical assessment of disease progression

Routine monitoring and assessments are crucial to assess any changes that can occur as patients progress through life. Comprehensive annual reviews are offered which include pulmonary, nutritional and psychological assessments [39]. Lung function is primarily singled-out as this has a significant impact on the patient’s quality of life, especially if their lung disease has significantly advanced. To assess this, pulmonary testing is carried out through spirometry. This measures forced expiratory volume in 1 second (FEV₁), forced expiratory flow (FEF)₂₅₋₇₅, and forced vital

<table>
<thead>
<tr>
<th>Classification</th>
<th>CFTR defect</th>
<th>Mutation examples</th>
<th>Required approaches</th>
<th>Drug required (Approved?)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I</td>
<td>No functional CFTR protein/mRNA</td>
<td>G542X, W1282X, R553X</td>
<td>Salvage protein synthesis</td>
<td>Bypass therapy (no), Read through agents (no)</td>
</tr>
<tr>
<td>Class II</td>
<td>CFTR trafficking defect</td>
<td>ΔF508, G551D, N1303K</td>
<td>Correct protein folding</td>
<td>Corrector (yes)</td>
</tr>
<tr>
<td>Class III</td>
<td>Impaired gating</td>
<td>G551D, V508F, S549N</td>
<td>Recover channel conductance</td>
<td>Potentiator (yes)</td>
</tr>
<tr>
<td>Class IV</td>
<td>Decreased channel conductance</td>
<td>R334W, R117H, S1235R</td>
<td>Recover channel conductance</td>
<td>Potentiator (only for R117H)</td>
</tr>
<tr>
<td>Class V</td>
<td>Reduced production of CFTR</td>
<td>A455E, 1889-1896ΔG</td>
<td>Improve maturation/correct splicing</td>
<td>Anti-sense oligonucleotides (no), Corrector (no), Amplifier (no)</td>
</tr>
<tr>
<td>Class VI</td>
<td>Decreased CFTR stability</td>
<td>Q1412X, 4279 insA</td>
<td>Promote protein stability</td>
<td>Stabilisers (no)</td>
</tr>
</tbody>
</table>

CFTR, cystic fibrosis transmembrane conductance regulator.
capacity (FVC), with oxygen saturation measured to further determine lung condition. Weight and height are used as key indicators in evaluating growth and nutritional status. These go alongside tests that look for CF-related disorders such as diabetes and liver disease [40]. Sputum samples are also taken for microbiological analysis or, if this is not possible, cough swabs or nasopharyngeal aspirates can be used. Any significant abnormalities found in any of these tests may call for clinicians to alter treatment.

Alongside this, regular routine reviews are carried out. These are more frequent in earlier life and start immediately after diagnosis. In the first month of life these reviews occur weekly, progressing to monthly during the first year, and then incrementing to every 3 to 6 months as patients progress into adulthood. These reviews look at treatment adherence, quality of life and any complications or concerns patients may have [41]. Sudden onset of pulmonary exacerbations can regularly appear, and they are normally caused by an acute pulmonary infection. These often need to be clinically managed, and so chest X-rays may be beneficial in looking for radiological abnormalities.

Non-pharmacological management

Patients can implement several techniques that may help to improve their symptoms. Physiotherapy is performed daily, which helps to clear the airways and loosen mucus in the lungs. It can also be adapted to individual needs, as certain techniques can improve problems such as urinary incontinence and inhaled medication compliance [42,43]. Frequent exercise is strongly advised as this can loosen up sputum, increase respiratory muscle endurance and reduce lung residual volume [44,45].

It is highly important for patients to maintain good nutrition, as a healthy body weight has been directly linked to better lung function and fewer chest infections [46]. Unfortunately, due to the GI tract being congested, malabsorption is a common problem especially in early life [15,47]. To help manage this, more calories need to be consumed and digestive enzyme replacements are given to help aid the breakdown of food [48]. Even with supplementation, CF can increase the body’s energy requirements by over 100% which is challenging for many, particularly for those with poor appetite [49]. Performing these tasks can be a burden, which partially explains why psychological distress is frequently seen in CF patients and their caregivers [50,51]. Prevalence data shows that these problems are 2-3 times more prevalent than in the general background population [52-54]. To combat this, countries such as the UK have introduced guidelines where annual reviews assess wellbeing, quality of life and treatment adherence [55].

Established drug therapies

Until recently, patients have relied on therapies that treat the symptoms rather than the underlying cause. Such options have included the inhalation of mucolytic agents such as hypertonic saline, rhDNase and mannitol powder. These aim to thin the mucus on the lung epithelium, making it easier to cough out. Hypertonic saline works by increasing the amount of salt in the airways, which attracts water and thins the mucus [56]. It is available in different concentrations of 3%, 3.5% and 7%. People who are 6 years or older or those with FEV1 greater than 40% percent predicted can be offered this. Although the guidelines do not advocate for its use among those younger than 6, a recent study has shown that inhaled hypertonic saline improved lung clearance in children aged 3-6 years and could be a suitable early intervention [57].

rhDNase (Dornase alfa; Pulmozyme®) is approved for people 5 years and older. It works as an enzyme which hydrolyzes the DNA in the mucus and reduces sputum viscoelasticity [58]. Comparisons to hypertonic saline show superiority in improving lung function in several trials, with one indicating that rhDNase given on alternative days rather than daily is equally effective [59-61]. Mannitol powder has also been recommended as an option, although stricter criteria have been put on its usage. The criteria are as follows: inadequate response to rhDNase, declining lung function (>2% decline in FEV1 annually), and where other osmotic agents are not appropriate. The exact mechanism of action is unknown, though it is thought to change the viscoelastic properties of mucus. It does this by rehydrating the PCL, thereby increasing clearance through mucociliary activity [62].

Bronchodilators can be used alongside mucolytics as these widen the airways, allowing mucus to move easily from smaller airways to larger ones. These also help with bronchospasms which are a common side effect of inhaled treatments [63].

Molecular therapies for CF

Recently, a number of new drugs have been made available which have shown favourable results in several Phase III clinical trials [64-79], as shown in Table 2. These have been designed to target the underlying mechanism responsible for creating the ineffective CFTR protein.

The first therapeutic drug that has demonstrated significant clinical effects is Ivacaftor (Kalydeco®). Developed by Vertex Pharmaceuticals, it is the first of its kind to target the underlying gene defect. It works by modulating inefficient CFTR channels at the cell surface causing them to open [80]. The main target is the G551D mutation, a Class III defect and the most prevalent gating mutation [81]. Several completed studies highlight the significant improvements in percent predicted forced expiratory volume in one second (ppFEV1) and other clinical outcomes in class III and IV mutations [64-68]. The main drawback of Ivacaftor is that there is no supportive evidence that it is effective for those with a F508del mutation, which accounts for the majority of cases in Europe and North America [4,10,13]. This Class II mutation causes ineffective protein folding. To target this, Vertex has designed Lumacaftor which acts as a chaperone during protein folding, increasing the number of efficient CFTR proteins at the cell surface [82]. Evidence shows that as a monotherapy, it is ineffective at providing significant improvements in lung function, but may have potential for use in combination with other drugs [83]. To fully combat the F508del mutation, Vertex has created co-formulated combinations aimed at maximising the number of effective CFTR channels. The first of these is Ivacaftor/Lumacaftor (Orkambi®), which utilises the dual action of both drugs by helping the protein fold correctly and then modulating the channel after it has reached the cell membrane. Some Phase III studies involving Orkambi® have demonstrated significant improvements in ppFEV1 [72-74], although others have not identified such significance [69-71]. Another combination treatment is Tezacaftor/Ivacaftor (Symdeko® in US, Symkevi® in EU). Tezacaftor has been designed to facilitate the processing and trafficking of the CFTR protein towards the cell surface. In the two biggest completed Phase III studies, EVOLVE and EXPAND, the Tezacaftor/Ivacaftor group showed significant improvements in ppFEV1 [76-77], although a smaller study showed no significant increase in ppFEV1 [75].

Vertex has recently produced a triple combination therapy consisting of a combination of Elexacaftor/Tezacaftor/Ivacaftor
(Trikafta® in US, Kaftrio® in EU) that is used in a combination regimen with ivacaftor. Elexacaftor, like Tezacaftor, is a CFTR correcor but binds to a different site and facilitates the cellular processing and trafficking of the CFTR protein to the cell surface [84]. Of the two completed Phase III clinical trials shown in Table 2, greater improvements have been shown in the average ppFEV1, and CFTR score than either Orkambi® or Symkevi® [78-79]. Significant reductions in sweat chloride concentration have also been shown compared to trials involving the other dual therapies. Although these molecular therapies have shown great benefit, there are several side effects that need to be considered before starting treatment. Common side effects associated with these drug therapies include headaches, upper respiratory tract infections, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness [64-79]. One of the more severe side effects is the worsening of liver function, as these treatments have been shown to increase blood liver enzyme levels [85,86]. This is indicative of hepatic impairment. Blood tests assessing liver function must be undertaken before initiation, then every 3 months during the first year, followed by annual appointments. These therapies have also been shown to increase the risk of cataracts in some children and adolescents [87-90], so an eye examination should be performed before and during treatment. The therapeutic effectiveness of these therapies can vary if in comitant use with

**Table 2. Published phase III clinical trials for new drug therapies for cystic fibrosis (up to June 2020).**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Study Name</th>
<th>Outcome(s)</th>
<th>Age</th>
<th>Length</th>
<th>Mutation</th>
<th>Main finding in treatment group</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivacaftor (Kalydeco®)</td>
<td>KONDUCT (n=49)</td>
<td>I. Safety II. Change in ppFEV1</td>
<td>≥6 Yrs</td>
<td>24W</td>
<td>R117H</td>
<td>Mean absolute ppFEV1 significantly increased for those ≥18 years by 5.9% (95% CI 1.15-8.78%), not in those aged 6-11 years.</td>
<td>64</td>
</tr>
<tr>
<td></td>
<td>CONNECTION (n=38)</td>
<td>I. Change in ppFEV1</td>
<td>≥6 Yrs</td>
<td>24W</td>
<td>Non-G551D Gating</td>
<td>Significant improvement in BMI and sweat chloride. ppFEV1 with model-adjusted absolute mean increased by 10.7% (95% CI 7.3-14.1%) at 8W and was maintained through 24W.</td>
<td>65</td>
</tr>
<tr>
<td></td>
<td>ENVISION (n=52)</td>
<td>I. Change in ppFEV1</td>
<td>6-11 Yrs</td>
<td>48W</td>
<td>G551D</td>
<td>Significant increase in adjusted ppFEV1 when compared to placebo (10.7% vs. 0.7%, P &lt; 0.001). Mean gain of 2.5 kg more than placebo with sweat chloride levels significantly reduced.</td>
<td>66</td>
</tr>
<tr>
<td></td>
<td>PERSIST (n=192)</td>
<td>I. AE’s II. Change in ppFEV1</td>
<td>≥6 Yrs</td>
<td>144W</td>
<td>G551D</td>
<td>Significant improvement in lung function; change in LCI2.5 by -1.09 units (95% CI 0.4-4.4%) using least square mean analysis. Some AEs were higher in intervention groups.</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td>STRIVE (n=161)</td>
<td>I. Change in ppFEV1</td>
<td>≥12 Yrs</td>
<td>48W</td>
<td>G551D</td>
<td>Significant increase in ppFEV1 at 24W (10.6%) and maintained at W8. PEx reduced by 55% and sweat chloride was significantly reduced. Mean gain of 2.7kg compared to placebo.</td>
<td>68</td>
</tr>
<tr>
<td>Lumacaftor/ Ivcactor (Orkambi®)</td>
<td>VX15-609-115 (n=60)</td>
<td>I. AE II. Sweat chloride III. Change in ppFEV1</td>
<td>2-5 Yrs</td>
<td>24W</td>
<td>F508del</td>
<td>Both drugs well tolerated. Mean sweat chloride concentrations decreased on average 31.7 mmol/L</td>
<td>69</td>
</tr>
<tr>
<td></td>
<td>VX13-809-011 (n=38)</td>
<td>I. AE II. Change in ppFEV1</td>
<td>6-11 Yrs</td>
<td>24W</td>
<td>F508del</td>
<td>Well tolerated. No significant change in ppFEV1, but significant improvements in BMI, CFQ-R scores and sweat chloride level reduced by 24.8 mmol/L.</td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>VX14-809-106 (n=46)</td>
<td>I. AE II. Change in ppFEV1</td>
<td>≥12 Yrs</td>
<td>24W</td>
<td>F508del</td>
<td>Severe lung disease patients receiving half dose had less respiratory events with shorter duration. ppFEV1 was similar to baseline from 4W onward.</td>
<td>71</td>
</tr>
<tr>
<td></td>
<td>TRAFFIC and TRANSPORT (n=1180)</td>
<td>I. Change in ppFEV1</td>
<td>≥12 Yrs</td>
<td>24W</td>
<td>F508del</td>
<td>Significant improvements in ppFEV1 in those with varying degrees of lung function. Significant improvements in BMI and PEx. Some AEs were higher in intervention groups.</td>
<td>72</td>
</tr>
<tr>
<td></td>
<td>VX14-809-109 (n=206)</td>
<td>I. Lung clearance II. Change in ppFEV1</td>
<td>6-11 Yrs</td>
<td>24W</td>
<td>F508del</td>
<td>Significant improvements in lung function; change in LCI2.5 by -1.09 units (95% CI -1.43 to -0.75) and absolute change ppFEV1 by 2.4% (95% CI 0.4-4.4%) using least square mean analysis. ppFEV1 was maintained from continued treatment. PEx rate remained lower than placebo. Annual ppFEV1 decline was reduced.</td>
<td>73</td>
</tr>
<tr>
<td></td>
<td>PROGRESS (n=1630)</td>
<td>I. AE II. Change in ppFEV1</td>
<td>≥12 Yrs</td>
<td>96W</td>
<td>F508del</td>
<td>Both drugs well tolerated. Mean sweat chloride concentrations decreased on average 31.7 mmol/L</td>
<td>74</td>
</tr>
<tr>
<td></td>
<td>VX15-661-113 (n=70)</td>
<td>I. Safety II. Change in ppFEV1 III. Change in ppFEV1</td>
<td>6-11 Yrs</td>
<td>24W</td>
<td>F508del + 1 F/RF</td>
<td>Well tolerated. Significantly improved sweat chloride levels and CFQ-R scores. Mean absolute change ppFEV1 remained stable. PEx were 55% lower. Absolute and relative mean changes in ppFEV1</td>
<td>75</td>
</tr>
<tr>
<td></td>
<td>EVOLVE (n=510)</td>
<td>≥12 Yrs</td>
<td>24W</td>
<td>F508del</td>
<td></td>
<td>Significantly improved by 4.6% (95% CI 3.1-4.8%) and 6.8% (95% CI 5.3-8.3%) respectively (P&lt;0.001 for both).</td>
<td>76</td>
</tr>
<tr>
<td></td>
<td>EXPAND (n=248)</td>
<td>I. Change in ppFEV1</td>
<td>≥12 Yrs</td>
<td>24W</td>
<td>F508del + 1 F/RF</td>
<td></td>
<td>Absolute change ppFEV1 was significantly increased in Ivcactor/Ivcactor group by 6.2% (95% CI 5.7-8.8%) and Ivcactor group by 4.7% (95% CI 3.7-5.8%) compared to placebo.</td>
</tr>
<tr>
<td></td>
<td>VX17-445-102 (n=403)</td>
<td>I. Change in ppFEV1</td>
<td>≥12 Yrs</td>
<td>24W</td>
<td>F508del + 1 F/RF</td>
<td></td>
<td>ppFEV1 was significantly higher at 4W (13.8%) and 24W (14.3%) compared to placebo.</td>
</tr>
<tr>
<td></td>
<td>VX17-445-103 (n=111)</td>
<td>I. Change in ppFEV1 II. Sweat Chloride</td>
<td>≥12 Yrs</td>
<td>4W</td>
<td>F508del</td>
<td></td>
<td>Elexacaftor/Tezacaftor group had significant increase in ppFEV1 of 10.0% (95% CI 7.4-12.6%) and significant improvement in sweat chloride levels by 45.1 mmol/L (95% CI 50.1 to -40.1) compared to Tezacaftor/Tezacaftor group.</td>
</tr>
</tbody>
</table>

*Ref., Reference; n, number of enrolled participants; ppFEV1, percent predicted forced expiratory volume in one second; CI, confidence intervals; Yrs, years; W, weeks; BMI, body mass index; AE, adverse effects; PEx, pulmonary exacerbations; CFQ-R, cystic fibrosis questionnaire-revised; LCI, lung clearance index; RCT, randomised control trial; F/RF, residual function mutation; F/MF, minimal function mutation.*
other medications that induce or inhibit CYP3A4 enzymes. Therefore, a drug history and review would have to be undertaken before starting any treatment.

The therapeutic indications for these new molecular therapies are shown in Table 3. These include the authorised use from the US Food and Drug administration, and European Medicines Agency. Currently in the EU, Kalydeco’s approval covers the medication’s use in children as young as six months, while the approval for Symkevi® allows its use in patients aged 12 or older. This may soon be reduced to 4 months for Kalydeco® and 6 years for Symkevi® as this has been recommended to be green lighted by the European Medicines Agency [91,92].

**Table 3. Authorised use of new drug therapies in the EU and US.**

<table>
<thead>
<tr>
<th>Drug (trade name)</th>
<th>EMA therapeutic indication</th>
<th>US FDA therapeutic indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivcaltor (Kalydeco®)</td>
<td>Kalydeco® is used on its own to treat cystic fibrosis in patients aged 6 months and above who have one of the following mutations in the CFTR gene: R117H, G551D, G1244E, G178R, G551S, S1251N, S1255P, S494N and S49R.</td>
<td>Kalydeco® is used on its own to treat cystic fibrosis in patients aged 4 months and over who have one of 10 mutations in the CFTR gene: G551D, G178R, S494N, S49R, G551S, G1244E, S1251N, S1255P, G144B or R117H.</td>
</tr>
<tr>
<td>Lumacaftor/ivcaltor (Orkambi®)</td>
<td>Orkambi® tablets are indicated for the treatment of CF in patients aged 2 years and older who are homozygous for the F508del mutation in the CFTR gene. Orkambi® granules are indicated for the treatment of CF in children aged 2 years and older who are homozygous for the F508del mutation in the CFTR gene.</td>
<td>Orkambi® tablets are indicated for the treatment of CF in patients aged 2 years and older who are homozygous for the F508del mutation in the CFTR gene. Orkambi® granules are indicated for the treatment of cystic fibrosis CF in children aged 2 years and older who are homozygous for the F508del mutation in the CFTR gene.</td>
</tr>
<tr>
<td>Tezacaftor/ivcaltor (Symdeko® in US, Symkevi® in EU)</td>
<td>Symkevi® is indicated in a combination regimen with ivcaltor for the treatment of patients of CF aged 12 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the CFTR gene: P675L, R117C, L200W, R334Q, A455E, D1067, T1172 +3A→G, S654L, S977E, K1070N, D1152H, 2789+5G→A, 3272+6A→G, and 3849-10kbC→T.</td>
<td>Symdeko® is indicated in a combination regimen with ivacaftor for the treatment of patients with CF aged 6 years and older who are homozygous for the F508del mutation or who have one or more of the following mutations in the CFTR gene: A555E, E508Q, R752W, A1177T, E1313K, R117C, D1146E, F1642W, R344H, D1100H, F507L, R334Q, E574Q, K1047R, R1100Q, D1152H, L206W, S956L, D1270N, P67L, S977E, T1172 +3A→G, 3272+6A→G, 3849-10kbC→T, E831X, 2789+5G→A, 3849-10kbC→T.</td>
</tr>
<tr>
<td>Flexacaftor/ivcaltor (Trikafta® in US/Kaftrio® in EU)</td>
<td>Kaftrio® is indicated in a combination regimen with ivacaftor for the treatment of CF in patients aged 12 years and older who have at least one F508del mutation in the CFTR gene.</td>
<td>Trikafta® is indicated in a combination regimen with ivacaftor for the treatment of CF in patients aged 12 years and older who have at least one F508del mutation in the CFTR gene.</td>
</tr>
</tbody>
</table>

Inhaled corticosteroids

The use of inhaled corticosteroids (ICS) as anti-inflammatory agents in both adults and children with CF is not often
recommended. There is no evidence to suggest that these improve lung function or quality of life [104]. In fact, there is some evidence to suggest there is an adverse effect on growth at high dosages [105]. Therefore, the use of corticosteroids should be restricted to those with symptomatic wheezing if deemed to be beneficial. Regular assessments will be needed to identify if the treatment is working, as well as to identify any side effects. However, it is important to consider that corticosteroids are heterogeneous, resulting in different side-effect profiles. An example of this is the increased risk of pneumonia in patients taking fluticasone, alone or in combination with salmeterol, whilst there is no similarly reported increased risk of pneumonia in patients taking a budesonide/formoterol combination. The use of some steroids can therefore be safer than others and careful attention must be paid to the side effect profiles of individual ICS [106].

### Lung transplantation

Due to the absence of a cure, there may be a point where conventional treatments no longer work. In this scenario, medical staff may then have to decide whether a lung transplant is the most viable option. Other organs such as the liver or pancreas are also examined for possible transplantation, but only if necessary. There is no way to determine how long a patient will have to wait for a transplant. This would depend upon how the transplant team have evaluated their condition, but also on the availability of a donor that is a good match for the patient. For most, this takes several months where only two in three will be successful in having a transplant [107]. Survival rates at 5 years after the procedure are approximately 60% among CF patients, with many of these living for at least 10 years [108].

### Antibiotic treatment and prophylaxis

As well as airway obstruction, CF is characterised by chronic bacterial infections and inflammatory exacerbations [15,109]. It is not known whether the predisposition to infection is caused by decreased ASL alone, or whether environmental factors or even immunological defects are at play. What becomes clear however, is that CF lung pathogenesis begins with the altered lung environment triggered by the abnormal CFTR.

The microbiome of the lung environment in CF is different from that of healthy people, as the diversity changes as patients get older and their lung disease progresses [110]. The traditional view proposes that bacterial communities become less diverse with antibiotic usage and advancing lung disease [111]. The community thereby becomes dominated with bacteria such as *Staphylococcus aureus* (*S. aureus*), opportunistic pathogens such as *Pseudomonas aeruginosa* (*P. aeruginosa*), *Haemophilus influenzae* (*H. influenzae*), *Stenotrophomonas maltophilia* (*S. maltophilia*), *Burkholderia cepacia* (*B. cepacia*), and *Achromobacter xylosoxidans* (*A. xylosoxidans*), with *P. aeruginosa* being the predominate lung infection in CF [112]. All of these, with the exception of *S. aureus*, are gram negative and are associated with steep declines in lung function, increased risk of exacerbations and greater risk of mortality [113].

Recognition of the diverse microbiota raises questions on how best to approach antibiotic treatment. In terms of antibiotic resistance, *S. maltophilia*, *B. cepacia* and *P. aeruginosa* have been found to be difficult to kill due to their vast array of resistance mechanisms [114]. These include Beta-lactamases, efflux pumps, and biofilm formation which increase their resistance to aminoglycosides, fluoroquinolones and Beta-lactams [115]. In some cases, especially in early life, antibiotic prophylaxis may be given to prevent infection and lung damage. Any changes to the treatment regimen will have to be evaluated beforehand. This will look at the potential side effects that may arise, such as the possibility of drug toxicity when using drugs such as Streptomycin, Kanamycin and Amikacin to treat non-tuberculous mycobacteria. These drugs can have adverse effects on auditory, vestibular, renal and neuromuscular function [116]. These also have been shown to interfere with CY3PA4 enzymes, and therefore patients being treated with the new molecular therapies (Kalydeco®, Orkambi®, Symkevi®/Symdeko®, or Trikafta®/Kaftrio®) need to be closely monitored.

### Ongoing clinical trials

In the first part of this review we have discussed the current management of CF. Next, we will expand into novel treatment possibilities, exploring how these could improve upon treating the underlying mechanism of CF. Many clinical trials are currently underway, which look at treatments that aim to improve pulmonary function, as shown in Table 4. This does not include trials aiming to treat pulmonary exacerbations or lung infections, but the compounds may reduce the number of these as a secondary effect.

### Emerging molecular therapies

There is ongoing development on a variety of new potentiators and correctors. Alongside this, entirely new classes of CFTR modulators are in development, primarily read-through agents and CFTR amplifiers. Potentiators and correctors currently in development are shown in Table 4. ABBV-3067 (formerly known as GLPG-3067) has completed Phase I clinical trials (NCT03128606) and preliminary results seem to indicate that the drug was well tolerated [117]. As shown in Table 4, it is now in Phase II clinical trials alone and in combination with ABBV-22222 (formerly known as GLPG-2222), a corrector that demonstrated advantages over the first generation correctors Lumacaftor and Tezacaftor in preclinical studies [118]. The new CFTR modulators PTI-801, PTI-808 and PTI-428 are being tested in combination, as seen in Table 4. PTI-801 is a corrector, PTI-808 is a potentiator, and PTI-428 is a novel class of CFTR modulator known as an “amplifier”. This triple combination has completed Phase II trials in patients with at least one copy of the F508del mutation (NCT03251092), with a reported significant improvement in ppFEV1 and reduction in sweat chloride concentration [119]. There are now plans to move ahead with two Phase III clinical trials; the MORE (Modulator Options to RestorE CFTR) trial for subjects that are homozygous for F508del to confirm the efficacy of the triple combination and the CHOICES (Crossover trial based on Human Organoid Individual response in CF) trial that aims to develop the area of personalised medicine in CF [120].

### CFTR amplifiers

Of particular significance is the amplifier PTI-428. Amplifier agents work to increase the levels of CFTR protein by stabilising CFTR mRNA. The very early experimental compound known as PTI-1CH acted in a mutation-agnostic fashion and demonstrated efficacy in preclinical studies [121]. The development of PTI-428, a first-in-class amplifier, followed. In a Phase II study assessing the safety and efficacy of PTI-428 in patients taking Orkambi®, the test group exhibited a 5.2% increase in mean absolute improvement in...
Table 4. Current active and/or recruiting studies for drug therapies for cystic fibrosis (up to June 2020).

<table>
<thead>
<tr>
<th>Intervention drug(s)</th>
<th>Age</th>
<th>Phase</th>
<th>Drug action</th>
<th>Allele mutation</th>
<th>Trial no.</th>
<th>Status</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELX-02</td>
<td>≥ 18 years</td>
<td>II</td>
<td>ERSG</td>
<td>≥ 1 G542X</td>
<td>NCT04126473</td>
<td>Recruiting</td>
<td>Exna Pharmaceuticals</td>
</tr>
<tr>
<td>Orkambi®</td>
<td>≥ 12 years</td>
<td>-</td>
<td>Potentiator/corrector</td>
<td>2 F508del</td>
<td>NCT0139457</td>
<td>Recruiting</td>
<td>Assistance Publique - Hôpitaux de Paris</td>
</tr>
<tr>
<td>TEZ / IVA</td>
<td>≥ 6 years</td>
<td>III</td>
<td>Potentiator/corrector</td>
<td>≥ 1 F508del</td>
<td>NCT013751</td>
<td>Active, not recruiting</td>
<td>Vertex Pharmaceuticals</td>
</tr>
<tr>
<td>ELX / TEZ / IVA</td>
<td>≥ 12 years</td>
<td>III</td>
<td>Potentiator/corrector</td>
<td>≥ 1 F508del + 1 (F/MF)</td>
<td>NCT04447202</td>
<td>Active, not recruiting</td>
<td>Vertex Pharmaceuticals</td>
</tr>
<tr>
<td>ELX / TEZ / IVA</td>
<td>≥ 12 years</td>
<td>III</td>
<td>Potentiator/corrector</td>
<td>1 F508del + 1 (FG and F/R)</td>
<td>NCT0465885</td>
<td>Enrolling by invitation</td>
<td>Vertex Pharmaceuticals</td>
</tr>
<tr>
<td>ELX / TEZ / IVA</td>
<td>≥ 12 years</td>
<td>III</td>
<td>Potentiator/corrector</td>
<td>≥ 1 F508del</td>
<td>NCT0443806</td>
<td>Recruiting</td>
<td>Vertex Pharmaceuticals</td>
</tr>
<tr>
<td>ELX / TEZ / IVA</td>
<td>≥ 12 years</td>
<td>III</td>
<td>Potentiator/corrector</td>
<td>≥ 1 F508del</td>
<td>NCT0325574</td>
<td>Active, not recruiting</td>
<td>Vertex Pharmaceuticals</td>
</tr>
<tr>
<td>ELX / TEZ / IVA</td>
<td>≥ 6 years</td>
<td>III</td>
<td>Potentiator/corrector</td>
<td>≥ 1 F508del</td>
<td>NCT0416972</td>
<td>Active, not recruiting</td>
<td>Vertex Pharmaceuticals</td>
</tr>
<tr>
<td>ELX / TEZ / IVA</td>
<td>6 - 11 years</td>
<td>III</td>
<td>Potentiator/corrector</td>
<td>≥ 1 F508del + 1 (F/MF)</td>
<td>NCT0391779</td>
<td>Active, not recruiting</td>
<td>Vertex Pharmaceuticals</td>
</tr>
<tr>
<td>ELX / TEZ / IVA</td>
<td>≥ 12 years</td>
<td>II</td>
<td>Potentiator/corrector</td>
<td>Partial function mutations</td>
<td>NCT0306601</td>
<td>Recruiting</td>
<td>Emory University</td>
</tr>
<tr>
<td>PTI - 801</td>
<td>18 - 55 years</td>
<td>I</td>
<td>NEI</td>
<td>No specific mutation specified</td>
<td>NCT0374618</td>
<td>Recruiting</td>
<td>Chiesi Pharmaceuticals S.p.A.</td>
</tr>
<tr>
<td>CHF 1335</td>
<td>≥ 18 years</td>
<td>I</td>
<td>NEI</td>
<td>No specific mutation specified</td>
<td>NCT0401079</td>
<td>Recruiting</td>
<td>Santhera Pharmaceuticals</td>
</tr>
<tr>
<td>ABBV - 3087 +/- ABBV-2222</td>
<td>≥ 18 years</td>
<td>II</td>
<td>Corrector</td>
<td>2 F508del</td>
<td>NCT0386032</td>
<td>Recruiting</td>
<td>AbbVie</td>
</tr>
<tr>
<td>IONIS-ENaCrx</td>
<td>18 - 50 years</td>
<td>I/Ii</td>
<td>ENaC blocker</td>
<td>No specific mutation specified</td>
<td>NCT0347228</td>
<td>Recruiting</td>
<td>Ionis Pharmaceuticals</td>
</tr>
<tr>
<td>ARQ - ENaC</td>
<td>18 - 55 years</td>
<td>II/Ii</td>
<td>ENaC blocker</td>
<td>No specific mutation specified</td>
<td>NCT0417551</td>
<td>Recruiting</td>
<td>Arrowhead Pharmaceuticals</td>
</tr>
<tr>
<td>PTI-966/PTI-425/PTI-801</td>
<td>18 - 99 years</td>
<td>I/II</td>
<td>Potentiator/amplifier/corrector</td>
<td>≥ 1 F508del</td>
<td>NCT0352192</td>
<td>Active, not recruiting</td>
<td>Proteostasis Therapeutics</td>
</tr>
<tr>
<td>LADU-70</td>
<td>≥ 18 years</td>
<td>II</td>
<td>Anti-inflammatory</td>
<td>No specific mutation specified</td>
<td>NCT0265288</td>
<td>Recruiting</td>
<td>Laurent Pharmaceuticals</td>
</tr>
<tr>
<td>BI 125362</td>
<td>≥ 12 years</td>
<td>II</td>
<td>ENaC blocker</td>
<td>≥ 2 CF mutations</td>
<td>NCT0465904</td>
<td>Recruiting</td>
<td>Boehringer Ingelheim</td>
</tr>
<tr>
<td>Lenabasum (20 mg; 30mg)</td>
<td>≥ 12 years</td>
<td>II</td>
<td>Anti-inflammatory</td>
<td>No specific mutation specified</td>
<td>NCT0451045</td>
<td>Active, not recruiting</td>
<td>Corbus Pharmaceuticals</td>
</tr>
<tr>
<td>OligoG Dry powder</td>
<td>≥ 12 years</td>
<td>II/Ii</td>
<td>Mucolytic</td>
<td>No specific mutation specified</td>
<td>NCT0468448</td>
<td>Not yet recruiting</td>
<td>AlgPharma AS</td>
</tr>
<tr>
<td>OligoG Dry powder</td>
<td>≥ 12 years</td>
<td>II/Ii</td>
<td>Mucolytic</td>
<td>No specific mutation specified</td>
<td>NCT0422455</td>
<td>Recruiting</td>
<td>AlgPharma AS</td>
</tr>
<tr>
<td>CB-280</td>
<td>≥ 18 years</td>
<td>I/II</td>
<td>Anti-inflammatory</td>
<td>No specific mutation specified</td>
<td>NCT0427050</td>
<td>Not yet recruiting</td>
<td>Calithera Biosciences</td>
</tr>
<tr>
<td>MR50065</td>
<td>≥ 18 years</td>
<td>II</td>
<td>mRNA therapy</td>
<td>Two Class I or II mutations</td>
<td>NCT0375067</td>
<td>Recruiting</td>
<td>Translate Bio</td>
</tr>
</tbody>
</table>

ERSG, Endothelial ribosomal-selective glucoside; TEZ, Teazer; OA, beaclofen; ELX, Elexserter; F508del mutation; MF, minimal function mutation; G, gating mutation; RF, residual function mutation; NEI, neutrophil elastase inhibitor; ENaC, epithelial sodium channel; IVA, ivermectin B2 derivative; ELX, ivermectin B2; TEZ, tezithromycin; PTI, Pthiotide I; CB, CB-280; MR50065, MR50065; VX, VX-550; OA, baclofen; ELX, Elexserter; F508del mutation; MF, minimal function mutation; G, gating mutation; RF, residual function mutation; NEI, neutrophil elastase inhibitor; ENaC, epithelial sodium channel.
ppFEV₁ [122]. It continues to be tested in combination with PTI-808 and PTI-801.

**Readthrough agents**

Attention has also been given to the potential usage of readthrough agents, a novel type of CFTR modulator, in patients with CF resulting from nonsense mutations. These are point mutations that result in the introduction of a premature termination codon (PTC), resulting in the production of a truncated and dysfunctional protein. This problem can be bypassed using the natural process of translational readthrough (TR). TR involves the suppression of a PTC which allows for translation to continue beyond that PTC, subsequently resulting in the development of the full-length protein. Readthrough agents seek to exploit this natural phenomenon to allow for the frequent production of a full-length, fully functional protein [123]. Such agents are therefore potentially useful for patients that have CF caused by nonsense mutations, a large subset of CFTR mutation Class I, that cause the production of a truncated CFTR protein [124]. One readthrough agent that had been given particular attention is Ataluren, a readthrough agent that has been shown to be effective in nonsense mutation Duchenne muscular dystrophy (nmdMD) and is currently being used to treat specific patients with nmdMD [125]. However, Phase III trials showed no significant difference in mean relative change in FEVa, or sweat chloride concentrations, when comparing Ataluren to placebo for the treatment of CF resulting from nonsense mutations, and clinical development was subsequently halted [126,127]. Another readthrough agent known as ELX-02 demonstrated that it was able to produce readthrough of PTCs whilst preserving the fidelity of native stop codons (NSCs) in preclinical studies [128]. It is currently in Phase II clinical trials in CF patients with G542X nonsense mutations (NCT04126473).

**ENaC as an alternative target**

There is also potential to target other channels that contribute to the pathogenesis of CF. Due to the heavy role that ENaC plays in the dehydration of ASL in CF, there has been a focus on the potential for ENaC as a therapeutic target, for which there are no current therapeutics. Theoretically, the therapeutic inhibition of ENaC can reduce the hyperabsorption of sodium ions seen in CF, therefore rehydrating the ASL [129]. A variety of strategies can potentially be used to target ENaC. One established strategy is to simply directly inhibit ENaC, for which particular attention is being given to BI 1265162, a highly potent ENaC inhibitor that has shown efficacy in preclinical testing. Phase I clinical trials also demonstrated that the molecule was safe and well tolerated. It is currently the only ENaC inhibitor in Phase II clinical trials, in which it must now demonstrate clinical efficacy [130].

Another strategy is to inhibit channel activating proteases (CAP) which increase ENaC activation in CF and therefore contribute to sodium hyperabsorption [131]. Camostat was a CAP inhibitor initially used to provide proof of concept that CAP inhibitors can be used to attenuate ENaC function [132]. This has prompted the development of further compounds which may have the potential of replicating this effect. The two key inhibitors of ENaC-activating CAPs in development are QUB-L1 and NAP858, both of which have shown to improve ASL height and mucociliary clearance in preclinical studies. These compounds are only in pre-clinical development and their efficacy in vivo cannot be attested to [133].

Attention has also been given to the therapeutic potential of a protein called Short Palate Lung and Nasal Epithelial Clone 1 (SPLUNC1). SPLUNC1 is secreted by the airway epithelium and acts as an autocrine inhibitor of ENaC, a process which has the potential to be exploited [134]. SPX-101 is a key compound that was tested as a mimetic of SPLUNC1 as an attempt to replicate SPLUNC1’s ENaC-inhibitory effects [135]. Preclinical studies showed that SPX-101 acts to internalise all of ENaC’s subunits, leading to its inhibition [136]. Phase I trials on SPX-101 seemed to show that the compound was well tolerated and did not have systemic effects [137]. However, no further development on the compound is currently being undertaken and no other SPLUNC1 mimetics are currently in development [138]. Despite this, this is an area of inquiry that is relatively novel and therefore may have untapped potential.

Other lines of inquiry are looking into how ENaC production itself could be curtailed. One method to achieve this involves the usage of antisense oligonucleotides (ASOs). These have been shown to be efficacious in decreasing levels of mRNA that encode ENaC’s subunits, even in the presence of mucus, and reversing CF-like symptoms in mouse models [139]. The only antisense therapeutic for CF in development is IONIS-ENaC-2.5Rxs, which finished Phase I trials in June 2020 (NCT03647228). It was demonstrated to cause a mean 55.6% decrease in ENaC mRNA expression at a dose of 75mg in healthy patients, although full results are yet to be published [140]. As an alternative to ASOs, small interfering RNA (siRNA) can be delivered to the lung’s epithelial cells. In pre-clinical studies, these siRNAs have demonstrated efficacy in reducing ENaC mRNA levels, resulting in a decrease in the number of ENaC channels [141]. The key siRNA-based therapeutic in development is ARO-ENaC, which is currently in Phase I clinical trials (NCT04375514).

**Gene delivery approaches**

In contrast to a mutation specific approach, genetic manipulation has the potential to treat CF patients with mutations in any class. This strategy involves introducing the correct copies of CFTR DNA into the epithelial cells in the airways [142]. There are two components that are required for this. The first is a normal copy of the CFTR gene, along with the required regulatory sequences [143,144]. Focus was previously placed on viral approaches such as adenoviruses, adeno-associated viruses and Sendai virus, but these have proved ineffective due to the inefficient transduction of the CFTR gene [145]. Lentiviruses look more favourable, as they have shown sufficient capacity for a CFTR expression cassette and greater transducing capabilities [146]. Additionally, unlike adenoviral vectors, lentiviral vectors display low immunogenicity and are more amenable to repeated dosing [147]. In individuals with severe lung disease who may not respond to existing prescribed CFTR modulators, such as those with nonsense mutations, lentiviral vectors may offer certain advantages. However, lentiviruses do not naturally possess the surface proteins capable of recognising receptors on respiratory epithelia. To get around this, the UK CF Gene Therapy Consortium has created a simian immunodeficiency virus (SIV) pseudotyped with F and HN envelope proteins taken from a Sendai virus [148]. Currently, the Consortium is trying to design a Phase I/IIa trial using nasal epithelium as a surrogate organ, which will allow for easy monitoring of gene expression and safety. As well as the lungs, CFTR is expressed in other organs and viruses may have potential in targeting these. This is because viruses can only deliver DNA to specific cell types. The subsequent positive effects in nutritional and metabolic requirements are likely to reduce clinical problems and significantly improve quality of life.

More recently, attention has shifted towards non-viral vectors.
The most promising has been a formulation of Plasmid DNA expressing CFTR (pGM169) complexed with cationic liposome (GL67A). This biological agent was the first non-viral based gene therapy to undergo a clinical trial to detect functional changes. Following 12 monthly nebulised doses of PGM169/GL67A, there was a mild yet significant increase in ppFEV1 of 3.7% (0.1-7.3%, 95% Confidence Intervals; p<0.05) and the therapy was generally well tolerated [149]. This is only a modest increase, especially compared to other new drugs which show equal or better clinical outcomes [64-68,72-74,76-79]. It is therefore unlikely that the formulation will be suitable for use without further improvement in efficacy. In addition to this, increasing the frequency or dosage of this treatment could be explored, along with the addition of a CFTR potentiator. There were no treatment attributable adverse events seen, which could encourage the introduction of more potent vectors.

One of the main obstacles to the successful delivery of the DNA is the thick and tenacious mucus seen in CF, which acts as a barrier against penetration by exogenous molecules [150]. The answer to this problem may lie with compressing DNA into small, dense structures called nanoparticles (NPs) [151,152]. NPs, due to their size, can feasibly be utilised to overcome this obstacle as they are less likely to be hindered by the mucus mesh. To further enhance penetration, NPs can be coated with the electrostatically neutral molecules like polyethylene glycol (PEG) to reduce electrostatic interactions with mucins. They can also be coated in mucolytics, agents that cleave mucin fibres, to enhance mucus penetration [153]. This ultimately results in a greater amount of the DNA reaching the target epithelial cells, enhancing the efficacy and viability of gene therapy [154].

mRNA-based therapy

Another new proposal is MRT5005. This is designed to restore CFTR function by delivering correct copies of CFTR-encoded mRNA, via a nebuliser, to the lung epithelial cells. It is the first clinical stage mRNA product candidate developed to treat all patients regardless of their underlying genetic mutation, including those with limited or no CFTR protein. A Phase I/II trial is now underway [155], with interim data of the first single ascending dose phase having been published [156]. Twelve Participants, eleven of whom had at least one copy of F508del mutation, were split into four groups receiving different dosages (8, 16, and 24 mg) with one group receiving a placebo. In the eight-day period after dosing, the placebo group and 8 mg dose group showed no marked improvement in ppFEV1. In the 16 mg dose group, the mean maximum increase from baseline was 15.7% (5.8% Standard Deviation), with two participants in this group on a CFTR modulator during this period. In the 24 mg dose group, one patient experienced a maximum ppFEV1 increase of 21.4%, whilst two patients did not show any significant increase from their baseline.

CRISPR/Cas9 gene editing

CRISPR/Cas-9 based genome editing is a recent discovery with potential for correcting mutations in the CFTR gene [157]. Cas9 is a natural nuclease used for accurate DNA editing. It achieves this by complexing with a guide RNA (gRNA) that is specific to the target DNA, localising to the targeted DNA sequence, and then introducing a doubled-strand break (DSB) at the targeted site. This then activates the DNA DSB repair processes known as nonhomologous end-joining (NHEJ) and homology-directed repair (HDR), the latter of which most commonly utilises homologous recombination [158]. Donor DNA can then be provided, and this is used to repair the DSB, resulting in transgenic DNA [159]. Designing and testing gRNA has been met with high success rates and this technology has shown great promise for editing the human genome to treat CF [160].

Induced pluripotent stem cells with a CFTR mutation have been corrected using the CRISPR/Cas9 approach [161]. Stem cell niches have been described within the lungs, so it could be possible to obtain these cells from patients and correct the CFTR mutations, before reintroducing them back into their environmental niches [157]. Alternatively, viral and non-viral vehicles could be used for delivering CRISPR/Cas9 into pulmonary epithelial cells, although transfection issues will have to be overcome.

A new tool in CRISPR technology has been the development of Cpf1, also known as Cas12a. This differs from Cas9 as Cpf1 gRNA is shorter and requires only one single gRNA molecule, compared to Cas9 that requires two gRNAs [162]. This makes it easier to synthesise gRNA in vitro and package it into vectors. Cpf1 also cuts DNA to leave ‘sticky ends’, which allows DNA insertion to be more controllable and easier to work with, unlike Cas9 which leaves ‘blunt’ ends [163]. This method has shown great success in other genetic conditions such as Duchenne muscular dystrophy, where Zhang et al. successfully corrected the faulty gene in both mouse models and cells derived from affected patients [164]. Maule et al. provided proof of concept for the use of Cas12a in editing CFTR mutations. A minigene model was used to demonstrate that Cas12a could be utilised to effectively repair two mutations in the CFTR gene that result in splicing defects. Primary airway epithelial cells were also used to validate the efficacy of Cas12a as delivered by a lentiviral vector [165].

Using intravenous administration for delivery is not preferential as vectors will reach the alveoli, an area devoted for gas exchange, and not the surface epithelium of the bronchial tree, where the CFTR protein is more frequently expressed [166]. Therefore, inhaled deliveries are viewed as a suitable strategy of delivering these vectors.

Conclusion

By managing the symptoms with established therapies, CF patients are living longer than ever before, and with the approval of CFTR modulators, this is only likely to increase. At this moment, several new treatments are being evaluated through clinical trials, which aim to improve lung function by directly interacting with CFTR or by altering its downstream effects. These may give rise to a new generation of therapies which reduce the symptomatic problems that are frequently seen amongst sufferers.

Gene manipulating techniques and new molecular targets are also being explored. The use of genome editing using CRISPR/Cas9 technology has great potential, although it is still in the early stages of development, with obstacles in deliverance still needing to be overcome. There should also be more attention drawn to other organs and glands expressing CFTR mutations, as this will have vast nutritional and metabolic benefits if targeted successfully. Overall, there has been significant progress in the treatment of cystic fibrosis by attempting to restore the airways to a natural phenotype, either through restoring the function of existing CFTR proteins, modifying epithelial cells to produce normal CFTR, or by targeting alternative channels.

Acknowledgements

We would like to acknowledge Katie Jaques and William Secrett for proof-reading and editing.
Abbreviations

CF: cystic fibrosis;
CFTR: cystic fibrosis transmembrane conductance regulator;
NBD: nucleotide binding domain;
ENaC: epithelial sodium channel;
PNEC: pulmonary neuroendocrine cells;
ASL: airway surface liquid;
PCL: periciliary layer;
ML: mucus layer;
IRT: immunoreactive trypsinogen;
NPD: nasal potential difference;
FEV₁: forced expiratory volume in 1 second;
FVC: forced vital capacity;
ppFEV₁: percent predicted forced expiratory volume in one second;
ICS: inhaled corticosteroids;
PTC: premature termination codon;
TR: translational readthrough;
nmDMD: nonsense mutation Duchenne muscular dystrophy;
NSC: native stop codons;
CAP: channel activating proteases;
SPLUNC1: short palate lung and nasal epithelial clone 1;
ASO: antisense oligonucleotides;
siRNA: small interfering RNA;
NP: nanoparticle;
PbEG: polyethylene glycol;
gRNA: guide RNA;
DSB: doubled-strand break;
NHEJ: nonhomologous end-joining;
HDR: homology-directed repair.

References

9. ECFS Patient Registry Annual Data Report 2017. PDF


131. Matos AM, Matos P. Combination therapy in Phe508del CFTR: how many will be enough? J Lung Health Dis 2018;2:9-16.


143. Donnelly M, Parsons DW. Gene therapy for cystic fibrosis lung disease: overcoming the barriers to translation to the clinic. Front Pharmacol 2018;9,1381.


